Trial Profile
Phase 1 Study of Oral Decitabine and Tetrahydrouridine (THU) in Patients With High Risk Sickle Cell Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Decitabine (Primary) ; Tetrahydrouridine (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions; First in man
- 30 Jul 2018 Status changed from active, no longer recruiting to completed.
- 23 Jan 2018 Planned End Date changed from 1 Dec 2016 to 1 Jun 2018.
- 23 Jan 2018 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2018.